CGCaio Falk Giannotti

Caio Falk Giannotti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caio Falk Giannotti has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Benefício clínico e segurança do denosumabe no tumor de células gigantes do osso: revisão sistemática e meta-análise de braço único

    by Francisco Wellington Lopes Guimarães Filho, Marcelo De Toledo Petrilli, Jairo Greco Garcia, Reynaldo Jesus-Garcia Filho, Caio Falk Giannotti, Ariane Butke Brandt, Rafael Muller dos Santos

    O tumor de células gigantes do osso é uma neoplasia osteolítica localmente agressiva na qual o denosumabe se tornou uma opção sistêmica importante, porém ainda há incerteza quanto à durabilidade do controle e à segurança em esquemas do mundo real. Este estudo teve como objetivo sintetizar a efetividade e a segurança do tratamento baseado em denosumabe em pacientes com TCGO com maturidade esquelética. Realizou-se busca nas bases PubMed, EMBASE, Scopus e Cochrane Library estudos clínicos em texto completo e em língua inglesa que avaliaram denosumabe em pacientes com maturidade esquelética e tumor de células gigantes do osso até janeiro de 2026. Os desfechos primários foram benefício clínico e eventos adversos, e os desfechos secundários foram resposta por imagem, recidiva local e falha do tratamento. Uma meta-análise de braço único com modelo de efeitos aleatórios foi realizada, com estabilização de variância e ponderação pelo inverso da variância. A heterogeneidade foi quantificada pelo I², e intervalos preditivos e análises leave-one-out foram utilizados para avaliar a robustez. As análises de subgrupo foram limitadas ao desenho do estudo. Foram analisados 22 estudos, incluindo 1.170 pacientes. A taxa combinada de benefício clínico foi de 79,94% (IC 95% 74,21–85,02; I² 85,8%), e a taxa combinada de resposta por imagem foi de 72,72% (IC 95% 59,46–84,04; I² 97,2%). A recidiva local ocorreu em 24,49% dos pacientes (IC 95% 14,30–36,54; I² 96,5%) e a falha do tratamento em 10,36% (IC 95% 6,74–14,69; I² 57,0%). A taxa combinada de eventos adversos foi de 31,16% (IC 95% 6,76–63,08; I² 98,5%). A análise de subgrupo por desenho do estudo não reduziu de forma consistente a heterogeneidade, os intervalos preditivos foram amplos para a maioria dos desfechos e a meta-regressão utilizando idade média e a proporção de pacientes do sexo feminino não identificou moderadores significativos das estimativas combinadas. Observou-se que o denosumabe esteve associado a benefício clínico significativo e resposta radiológica em pacientes com maturidade esquelética e TCGO, porém, a durabilidade do controle e as estimativas de segurança variaram amplamente entre os estudos, ressaltando a necessidade de desfechos padronizados e de evidência prospectiva comparativa.

  • Open Access

    ANEURYSMAL BONE CYST: A CASE SERIES OF AN AGGRESSIVE BENIGN TUMOR

    by Caio Falk Giannotti, Nathalia Sundin Palmeira de Oliveira, Jairo Greco Garcia, Marcelo de Toledo Petrilli, Dan Carai Maia Viola, Reynaldo Jesus Garcia Filho

    Objective: The Aneurysmal Bone Cyst (ABC) is a benign yet aggressive bone tumor. This study aimed to evaluate sex, age, tumor location, tumor size, type of treatment (surgical, infiltration, embolization), and recurrence. Methods: Descriptive and quantitative statistical analyses were applied. The prevalence ratio and 95% confidence interval were calculated for the association between recurrence and sex, age, tumor size, Capanna's classification, and treatment type. Results: Twenty-three cases of ABCs were included, eleven (47.8%) females and twelve (52.2%) males. The mean age of treated patients was 11.2±1.8 years. Most cysts were located in the lower limbs (56.5%). The mean follow-up time was 42.8±14.01 months. The mean cyst diameter at the beginning of treatment was 5.58± 1.04 cm; of these, 17.4% were up to 3 cm, 43.5% from 3.1 to 6 cm, and 39.1% over 6 cm. Regarding initial treatment, 6 (26%) patients received infiltration, and in total 20 (86.9%) underwent surgery with bone grafting. The overall recurrence rate was 30.4%. No association was identified between recurrence and the variables studied (p ≥ 0.05). The epidemiological data obtained are consistent with pediatric cohorts reported in the literature. Conclusion: All evaluated methods are suitable for treating aneurysmal bone cysts. Level of Evidence IV; Case Series.


  • Open Access

    DIAGNOSTIC COMPETENCE IN BONE TUMORS: INFLUENCE OF ONCO-ORTHOPEDIC TRAINING

    by Julia Pozzetti Daou, Caio Falk Giannotti, Jairo Greco Garcia, Marcelo de Toledo Petrilli, Dan Carai Maia Viola, Reynaldo Jesus Garcia Filho

    Understanding the nature of musculoskeletal tumors is crucial for appropriate management and to secure a favorable prognosis. Orthopedists’ ability to identify these pathologies early and accurately is paramount. There is a requirement to raise awareness within the orthopedic community regarding the necessity of referrals to orthopedic oncology specialists, as delays in initiating proper treatment can compromise patient prognosis. Objective: The objective was to assess the capability of non-specialist orthopedists in identifying bone lesions suggestive of tumors and thus classify them by employing a questionnaire with radiographs and comparison with specialists. We aim to gain an in-depth understanding of their diagnostic competence and provide insights into teaching the subject in orthopedic residency programs. Methods: The sample consisted of 90 participants who answered the questionnaire: 18 orthopedic oncology specialists, 58 non-specialist orthopedists, and 14 orthopedic residents. Results: Specialists achieved an average accuracy of 12.50 ± 1.07, while non-specialists scored 10.00 ± 0.60 (p<0.001). Among non-specialists, there was no statistical significance when comparing whether they underwent specialization internship during residency nor the duration of the year of such training. The period since graduation also indicated no differences. Conclusion: This study highlights the importance of referring patients with suspected tumors to specialized orthopedists. Level of Evidence V; Expert Opinion.

  • Open Access

    RADIOGRAPHIC STUDY OF THE MEDIAL JOINT SPACE OF THE HIP IN LEGG-CALVÉ-PERTHES DISEASE

    by Rene Dujardin, Diego Praxedes DE Miras, Caio Falk Giannotti, Roberto Bezerra Nicolau, Eiffel Tsuyoshi Dobashi

    Objective: To evaluate medial joint space in affected and normal contralateral hips in patients with Legg-Calvé-Perthes disease (LCPD). Methods: To compare joint space, femoral head extrusion (FHE), medial space coefficient (MSC) of the hip, and femoral head width (FHW) in affected and normal hips, using 127 radiographs of patients with unilateral LCPD and considering age groups under and over six years old as well as their disease stage. Results: No statistically significant differences were observed regarding MSC between normal and affected hips regardless of disease staging. However, medial joint distance was significantly greater in affected hips than in normal hips. In the necrosis and fragmentation phase, distance from medial space in affected hips was significantly greater than in contralateral normal hips. Comparing only affected hips, MSC and FHW showed statistically significant differences and the group > 6 yo presented higher values. Among normal hips, the group < 6 yo presented a statistically significant difference considering the MSC and FHW. Conclusions: No statistically significant difference was found between the medial joint space of affected and normal hips, except for early stages of the disease (necrosis and fragmentation). The isolated use of radiographic study is insufficient in LCPD and the lack of complementation with other exams, such as magnetic resonance, can delay diagnosis of and onset of treatment for the disease. Level of Evidence III, Study of Non Consecutive Patients; without Consistently Applied Reference “Gold” Standard.